Search Results - Patrick Vermersch

Refine Results
  1. 1
    Social participation in patients with multiple sclerosis: correlations between disability and economic burden

    Social participation in patients with multiple sclerosis: correlations between disability and economic burden by Arnaud Kwiatkowski, Jean-Pierre Marissal, Madani Pouyfaucon, Patrick Vermersch, Patrick Hautecœur, B. Dervaux

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.

    Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. by D Caparros-Lefèbvre, S. Blond, Patrick Vermersch, N. Pécheux, J.D. Guieu, H Petit

    Published 1993
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose? by Patrick Vermersch, Jeremy Hobart, Catherine Dive‐Pouletty, Sylvie Bozzi, Steven Hass, Patricia K. Coyle

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Diagnosis and treatment of progressive multiple sclerosis: A position paper

    Diagnosis and treatment of progressive multiple sclerosis: A position paper by Carlo Pozzilli, Maura Pugliatti, Patrick Vermersch, Nikolaos Grigoriadis, Mona Alkhawajah, Laura Airas, Celia Oreja‐Guevara

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients

    Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients by Floriane Calocer, Olivier Dejardin, Arnaud Kwiatkowski, Bertrand Bourre, Patrick Vermersch, Patrick Hautecœur, Guy Launoy, Gilles Defer

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Artificial intelligence and science of patient input: a perspective from people with multiple sclerosis

    Artificial intelligence and science of patient input: a perspective from people with multiple sclerosis by Anne Helme, Dipak Kalra, Giampaolo Brichetto, Guy Peryer, Patrick Vermersch, Helga Weiland, Angela White, Paola Zaratin

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

    Clinical effects of natalizumab on multiple sclerosis appear early in treatment course by Ludwig Kappos, Paul O’Connor, Christopher H. Polman, Patrick Vermersch, Heinz Wiendl, Amy Pace, Annie Zhang, Christophe Hotermans

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

    Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study by Patrick Vermersch, R. Benrabah, Nicolás Schmidt, Hélène Zephir, Pierre Clavelou, Cyrille Vongsouthi, Patrice Dubreuil, Alain Moussy, Olivier Hermine

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

    Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study by Cristoforo Comi, Stuart D. Cook, Kottil Rammohan, Per Soelberg Sørensen, Patrick Vermersch, Abidemi Adeniji, Fernando Dangond, Gavin Giovannoni

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

    Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype by Bruno Brochet, Pierre Clavelou, Gilles Defer, de Sèze, Céline Louapre, Éloi Magnin, Aurélie Ruet, Catherine Thomas-Antérion, Patrick Vermersch

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

    Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study by Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Gıancarlo Comı, Fernando Dangond, Abidemi Adeniji, Patrick Vermersch

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study by Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Gıancarlo Comı, Fernando Dangond, Christine Hicking, Patrick Vermersch

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder?

    Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? by Didier Leys, Jean‐Pierre Pruvo, Maxime Parent, Patrick Vermersch, G Soetaert, M Steinling, A. Delacourte, A. Défossez, A. Rapoport, J Clarisse

    Published 1991
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Neurologic Manifestations in Primary Sjögren Syndrome

    Neurologic Manifestations in Primary Sjögren Syndrome by S. Delalande, de Sèze, A.L. Fauchais, É. Hachulla, Tanya Stojkovic, D. Ferriby, Sylvain Dubucquoi, Jean‐Pierre Pruvo, Patrick Vermersch, Pierre‐Yves Hatron

    Published 2004
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

    Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. by Philip Scheltens, Didier Leys, Frederik Barkhof, D. Huglo, H. C. Weinstein, Patrick Vermersch, Michaël Kuiper, M Steinling, Erik Ch. Wolters, Jaap Valk

    Published 1992
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

    Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis by Gıancarlo Comı, Stuart D. Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Andrew Galazka, Axel Nolting, Christine Hicking, Fernando Dangond

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

    Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review by Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, Patrick Vermersch, Hans‐Peter Hartung, Letizia Leocani, Thomas Berger, Bart Van Wijmeersch, Celia Oreja‐Guevara

    Published 2024
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper by Susana Otero-Romero, Jaume Sastre‐Garriga, Cristoforo Comi, Hans-Peter Hartung, Per Soelberg Sørensen, Alan J. Thompson, Patrick Vermersch, Ralf Gold, Xavier Montalbán

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  19. 19
    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial by Jerry S. Wolinsky, Xavier Montalbán, Stephen L. Hauser, Gavin Giovannoni, Patrick Vermersch, Corrado Bernasconi, Gurpreet Deol‐Bhullar, Hideki Garren, Peter Chin, Shibeshih Belachew, Ludwig Kappos

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

    A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis by Gavin Giovannoni, Gıancarlo Comı, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven J. Greenberg

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: